Overview

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Status:
Completed

Trial end date:
2021-02-19

Target enrollment:

Participant gender:

Summary

This study will look at the effect on the QTc interval and pharmacokinetics after multiple dosing in subjects with HER2-expressing metastatic and/or unresectable breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Collaborator:

AstraZeneca

Treatments:

Camptothecin
Immunoconjugates